Mutations in SARS-CoV-2 Spike could lead to greater infectivity, study shows
Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
List view / Grid view
Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
Using NMR spectroscopy, researchers have partially observed the structure of heat shock proteins that bind to proteins that cause Huntington's disease.
Researchers have synthesised peptides that function like a soluble chemokine receptor, blocking atherosclerosis in animal models.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
A study has used artificial intelligence to reveal adeno-associated virus (AAV) capsid variants for use in gene therapies.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
In a zebrafish model, researchers have found that the protein NAPMT can trigger muscle stem cells to proliferate and heal muscle damage.
CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
Researchers have developed a personalised medicine platform that could advance genomic medicine research for cancer.
A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.